AAV5-PAH Gene Therapy Clinical Study for Subjects With Phenylketonuria: Update

Clinical Stage and Regulatory Timeline

BMN-307 is an investigational gene transfer therapy intended to deliver its phenylalanine hydroxylase (PAH) gene to the liver tissue for the production of PAH enzyme protein. Biomarin is conducting a Phase 1/2 clinical trial (PHEARLESS) to evaluate the safety and efficacy of AAV-PAH gene therapy in subjects with PKU. On September 2020, Biomarin announced the dosing of the first patients in their clinical studies.

Viral Vector and Gene Construct: 

AAV5.-Liver-specific promoter- PAH. The PAH gene under the liver tissue-specific promoter that drives the expression in the liver tissue. AAV5 is an adeno-associated virus that has been previously used to deliver the gene into liver tissue and successful transgene expression. 

Clinical Phase:

Biomarin is currently conducting a Phase 1/2 (NCT04480567) open-label, dose-escalation study to evaluate the safety and efficacy of BMN307 in PKU subjects with PAH deficiency. The proposed sample size is 100 PKU subject with PAH deficiency for the study.

Outcome Measures

Primary Outcome Measure

  • Change from baseline in mean Plasma Phe levels

Secondary Outcome

  • Change from baseline in mean Plasma Phe levels
  • Change from baseline in dietary protein intake from intact food
  • Number of participants with treatment-emergent adverse event

Key Results from Phase 1/2a 
First Patient Dosed in September 2020

Efficacy 
Not available 

Durability:

Not available

Safety: Not available

Serious Adverse Events: N/A

Immunogenicity

Antibody Response:N/A

T cell Response (ELISpot): N/A

Non-Clinical  Data Based on 2019 RDDay Presentation

It was reported that AAV5-PAH administration resulted in lifetime correction of Phe level similar to wildtype in the Enu-2(pah knockout) mice and supported the clinical development of BMN 307 program (RDDay2019 Presentation). 

Reference

Clinicaltrial.gov

Biomarin Press Release